Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Menlo Therapeutics Inc (NASDAQ: MNLO) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Menlo Therapeutics Inc (NASDAQ: MNLO) concerning whether a series of statements by Menlo Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On April 9, 2018, the Company revealed that Phase 2 clinical trial of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis failed to meet its primary or key secondary efficacy endpoints. The trial showed no statistically significant difference between patients treated with serlopitant and patients treated with placebo.

Following this news, NASDAQ: MNLO fell $27.05 per share or over 76% to close at $8.17 on April 9, 2018.

Based in Redwood City, California, and founded in 2011 Menlo Therapeutics Inc focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States.

If you purchased shares of Menlo Therapeutics Inc (NASDAQ: MNLO) on or before April 9, 2018, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185